溶栓后出血评分的临床应用及进展

doi:10.3969/j.issn.1673-5765.2019.07.015

摘要/Abstract

摘要：

静脉溶栓是治疗缺血性卒中有效的方法。出血转化是静脉溶栓后严重的并发症之一。溶栓后出血评分是评估缺血性卒中患者溶栓后出血转化发生率的预测模型，它的3项评价指标分别为卒中患者的血糖水平、卒中后临床严重程度及影像学数据。本文介绍了溶栓后出血评分的3项预测因素与溶栓后出血转化的关系，并对该评分的临床应用及进展进行了综述。

文章导读： 溶栓后出血评分包含血糖、NIHSS评分及梗死范围3项变量，对缺血性卒中溶栓后出血转化风险的评测简单迅速，且其预测效能较高，临床可结合患者其他危险因素对出血转化风险进行评估，有助于个体化溶栓方案的选择。

关键词: 预测模型; 出血转化; 静脉溶栓; 缺血性卒中

Abstract:

Intravenous thrombolysis is an effective treatment way of acute ischemic stroke (AIS). Hemorrhagic transformation (HT) is a serious complication in AIS patients treated with intravenous thrombolysis. The hemorrhage after thrombolysis (HAT) score is a predictive model for evaluating the risk of HT after intravenous thrombolysis. The HAT score includes three related risk factors for HT: blood glucose levels, stroke severity (per NIHSS) and imaging data on admission. This article reviewed the relation of the three risk factors of HAT score to the symptomatic intracerebral hemorrhage in patients treated by intravenous thrombolysis, the progress and clinical application of this HAT score.

Key words: Predictive model; Hemorrhagic transformation; Intravenous thrombolysis;Ischemic stroke

刘琪，张玉梅. 溶栓后出血评分的临床应用及进展[J]. 中国卒中杂志, 2019, 14(07): 727-732.

LIU Qi, ZHANG Yu-Mei. Progress and Application of Hemorrhage Risk Score after Thrombolysis[J]. Chinese Journal of Stroke, 2019, 14(07): 727-732.

参考文献

[1] CATANESE L，TARSIA J，FISHER M. Acute

ischemic stroke therapy overview[J]. Circ Res，2017，

120（3）：541-558.

[2] SAVER J L，GORNBEIN J，STARKMAN S.

Graphic reanalysis of the two NINDS-tPA trials

confirms substantial treatment benefit[J]. Stroke，

2010，41（10）：2381-2390.

[3] The NINDS t-PA Stroke Study Group. Intracerebral

hemorrhage after intravenous t-PA therapy for

ischemic stroke[J]. Stroke，1997，28（11）：2109-2118.

[4] LOU M，SAFDAR A，MEHDIRATTA M，et al.

The HAT score：a simple grading scale for predicting

hemorrhage after thrombolysis[J]. Neurology，2008，

71（18）：1417-1423.

[5] BERGER C，FIORELLI M，STEINER T，et al.

Hemorrhagic transformation of ischemic brain tissue：

asymptomatic or symptomatic?[J]. Stroke，2001，32

（6）：1330-1335.

[6] HACKE W，KASTE M，FIESCHI C，et al.

Randomised double-blind placebo-controlled

trial of thrombolytic therapy with intravenous

alteplase in acute ischaemic stroke（ECASS Ⅱ）.

Second European-Australasian Acute Stroke Study

Investigators[J]. Lancet，1998，352（9136）：1245-1251.

[7] WAHLGREN N，AHMED N，DAVALOS A，et

al. Thrombolysis with alteplase for acute ischaemic

stroke in the Safe Implementation of Thrombolysis

in Stroke-Monitoring Study（SITS-MOST）：an

observational study[J]. Lancet，2007，369（9558）：

275-282.

[8] VACLAVIK D，VILIONSKIS A，JATUZIS D，et

al. Clinical outcome of cardioembolic stroke treated

by intravenous thrombolysis[J]. Acta Neurol Scand，

2018，137（3）：347-355.

[9] DEMCHUK A M，MORGENSTERN L B，

KRIEGER D W，et al. Serum glucose level and

diabetes predict tissue plasminogen activator-related

intracerebral hemorrhage in acute ischemic stroke[J].

Stroke，1999，30（1）：34-39.

[10] KASE C S，FURLAN A J，WECHSLER L R，

et al. Cerebral hemorrhage after intra-arterial

thrombolysis for ischemic stroke：the PROACT Ⅱ

trial[J]. Neurology，2001，57（9）：1603-1610.

[11] PARSONS M W，BARBER P A，DESMOND P

M，et al. Acute hyperglycemia adversely affects

stroke outcome：a magnetic resonance imaging and

spectroscopy study[J]. Ann Neurol，2002，52（1）：

20-28.

[12] SARWAR N，GAO P，SESHASAI S R，et

al. Diabetes mellitus，fasting blood glucose

concentration，and risk of vascular disease：a

collaborative meta-analysis of 102 prospective

studies[J]. Lancet，2010，375（9733）：2215-2222.

[13] TANNE D，KASNER S E，DEMCHUK A M，et al.

Markers of increased risk of intracerebral hemorrhage

after intravenous recombinant tissue plasminogen

activator therapy for acute ischemic stroke in clinical

practice：the Multicenter rt-PA Stroke Survey[J].

Circulation，2002，105（14）：1679-1685.

[14] WAHLGREN N，AHMED N，ERIKSSON N，et

al. Multivariable analysis of outcome predictors

and adjustment of main outcome results to baseline

data profile in randomized controlled trials：Safe

Implementation of Thrombolysis in Stroke-

MOnitoring STudy（SITS-MOST）[J]. Stroke，2008，

39（12）：3316-3322

[15] DEMCHUK A M，TANNE D，HILL M D，et al.

Predictors of good outcome after intravenous tPA for

acute ischemic stroke[J]. Neurology，2001，57（3）：

474-480.

[16] JAUCH E C，SAVER J L，ADAMS H P Jr，et al.

Guidelines for the early management of patients with

acute ischemic stroke：a guideline for healthcare

professionals from the American Heart Association/

American[J]. Stroke，2013，44（3）：870-947.

[17] LARRUE V，VON K R，DEL Z G，et al.

Hemorrhagic transformation in acute ischemic

stroke. Potential contributing factors in the European

Cooperative Acute Stroke Study[J]. Stroke，1997，28

（5）：957-960.

[18] TSIVGOULIS G，SAQQUR M，BARRETO A，et

al. Validity of HAT score for predicting symptomatic

intracranial hemorrhage in acute stroke patients with

proximal occlusions：data from randomized trials of

sonothrombolysis[J]. Cerebrovasc Dis，2011，31（5）：

471-476.

[19] 张新宇，王丽平，罗树生，等. 用HAT评分预测rt-PA

静脉溶栓治疗脑梗死后出血的临床研究[J]. 现代预

防医学，2011，38（6）：1181-1183，1186.

[20] 郭文超，潘速跃. 溶栓后出血评分对尿激酶溶栓治疗

后脑梗死患者出血转化的预测价值[J]. 实用心脑肺

血管病杂志，2014，22（8）：17-19.

[21] 姜超，徐俊. 急性缺血性卒中溶栓出血转化预测的模

型分析[J]. 医学理论与实践，2016，29（2）：150-151.

[22] STRBIAN D，ENGELTER S，MICHEL P，et al.

Symptomatic intracranial hemorrhage after stroke

thrombolysis：the SEDAN score[J]. Ann Neurol，

2012，71（5）：634-641.

[23] MENON B K，SAVER J L，PRABHAKARAN S，et

al. Risk score for intracranial hemorrhage in patients

with acute ischemic stroke treated with intravenous

tissue-type plasminogen activator[J]. Stroke，2012，

43（9）：2293-2299.

[24] STRBIAN D，MERETOJA A，AHLHELM F J，et

al. Predicting outcome of IV thrombolysis-treated

ischemic stroke patients：the DRAGON score[J].

Neurology，2012，78（6）：427-432.

[25] FLINT A C，CULLEN S P，FAIGELES B S，et al.

Predicting long-term outcome after endovascular

stroke treatment：the totaled health risks in vascular

events score[J]. Am J Neuroradiol，2010，31（7）：

1192-1196.

[26] MAZYA M，EGIDO J A，FORD G A，et al.

Predicting the risk of symptomatic intracerebral

hemorrhage in ischemic stroke treated with

intravenous alteplase：Safe Implementation

of Treatments in Stroke（SITS）symptomatic

intracerebral hemorrhage risk score[J]. Stroke，2012，

43（6）：1524-1531.

[27] CUCCHIARA B，TANNE D，LEVINE S R，et al.

A risk score to predict intracranial hemorrhage after

recombinant tissue plasminogen activator for acute

ischemic stroke[J]. J Stroke Cerebrovasc Dis，2008，

17（6）：331-333.

[28] SUNG S F，CHEN S C，LIN H J，et al. Comparison of risk-scoring systems in predicting symptomatic

intracerebral hemorrhage after intravenous

thrombolysis[J]. Stroke，2013，44（6）：1561-1566.

[29] ASUZU D，NYSTROM K，AMIN H，et al.

Comparison of 8 scores for predicting symptomatic

intracerebral hemorrhage after IV thrombolysis[J].

Neurocrit Care，2015，22（2）：229-233.

[30] 杜子强，邹宏丽，时圣桂，等. GRASPS、SEDAN、

HAT模型对非溶栓性脑梗死出血转化的预测价值

[J]. 生物医学工程与临床，2016，20（6）：576-582.

[31] WHITELEY W N，THOMPSON D，MURRAY G，

et al. Targeting recombinant tissue-type plasminogen

activator in acute ischemic stroke based on risk of

intracranial hemorrhage or poor functional outcome：

an analysis of the third international stroke trial[J].

Stroke，2014，45（4）：1000-1006.

[32] STRBIAN D，MICHEL P，SEIFFGE D J，et al.

Symptomatic intracranial hemorrhage after stroke

thrombolysis：comparison of prediction scores[J].

Stroke，2014，45（3）：752-758.

[33] 魏衡，余勇飞，周瑞，等. HAT、SEDAN评分及相关

脑血管病危险因素预测急性缺血性卒中溶栓后出血

性转化临床研究[J]. 中国现代神经疾病杂志，2015，

15（2）：126-132.

[34] 谷远峰，陈会生. 五种评分系统对急性缺血性脑卒中

静脉溶栓后出血转化风险预测差异的比较研究[J].

解放军医药杂志，2016，28（3）：26-32.